Dupilumab cuts both ways

Volume: 83, Issue: 1, Pages: 35 - 36
Published: Jul 1, 2020
Abstract
Dupilumab has revolutionized management of atopic dermatitis (AD). The human monoclonal antibody reduces T-helper cell type 2 inflammation by blocking the shared receptor subunit for interleukin (IL) 4 and IL-13. Dermatologists eagerly go “off-label” with new medications, especially when there is a good rationale to do so. Hendricks et al 1 Hendricks A.J. Yosipovitch G. Shi V.Y. Dupilumab use in dermatologic conditions beyond atopic dermatitis—a...
Paper Details
Title
Dupilumab cuts both ways
Published Date
Jul 1, 2020
Volume
83
Issue
1
Pages
35 - 36
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.